Merck Submits COVID Antiviral Pill for EUA

October 11, 2021

This morning, the pharmaceutical company Merck submitted an application for EUA of their COVID-19 oral antiviral pill. If accepted, this will become the first pill authorized by the FDA to treat COVID-19. Other FDA authorized COVID-19 treatments must be administered intravenously or via injection.
The antiviral, called Molnupiravir, will be used to treat mild-to-moderate COVID-19 in adults who are at risk of progressing to severe COVID-19, including hospitalization.

“Molnupiravir has been shown to be active in several preclinical models of SARS-CoV-2, including for prophylaxis, treatment, and prevention of transmission. Additionally, pre-clinical and clinical data have shown Molnupiravir to be active against the most common SARS-CoV-2 variants.”

Interim analysis of trial data has indicated that the antiviral cuts the risk of hospitalization and death by approximately 50%. 7.3% of patients who received the drug were hospitalized or died during the trial, versus 14.1% of those who received a placebo. Additionally, 0 deaths were reported in patients who received the antiviral, compared to 8 deaths in those who received a placebo, by day 29 of the trial. The trial was stopped after observing such positive results.

Molnupiravir has been compared to Tamiflu, an antiviral used to treat and prevent influenza.

Join Our Community!Stay Informed. Stay Hopeful.

Sign up for periodic emails with resources, insights, and updates on autoimmune disease and living with chronic illness.

By adding your phone number, you agree to receive text message updates. Msg & data rates may apply.